NicOx’ Naproxcinod Shows Differentiated 24-Hour Blood Pressure Profile After 13 Weeks Treatment

NicOx S.A. (Euronext Paris: COX) announced positive results from the 112 clinical pharmacology study in 299 patients with osteoarthritis (OA) and hypertension, which was designed to characterize the 24-hour blood pressure profile of naproxcinod in comparison to the two most widely used non-steroidal anti-inflammatory drugs (NSAIDs). At week 13, naproxcinod 750 mg bid showed a reduction in systolic blood pressure (SBP) of 2.7 mmHg compared to naproxen 500 mg bid and 3.

More: continued here

Filed under: Clinical Trials on January 3rd, 2009